Equasens (STU:PHF) Research & Development: €0.0 Mil (TTM As of Dec. 2025)


STU:PHF Equasens STU:PHF
77 GF Score
Price €34.95
GF Value €55.65
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Equasens Research & Development?

Equasens STU:PHF -0.29% 77 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates STU:PHF with a GF Score™ of 77/100 and a GF Value™ of €55.65 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Equasens's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Equasens  (STU:PHF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Equasens Research & Development Related Terms

Equasens Research & Development Historical Data

* Premium members only.

The historical data trend for Equasens's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Equasens Research & Development Chart

Equasens Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Equasens Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:PHF
77GF Score
Equasens STU:PHF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Equasens Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Equasens (STU:PHF) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Equasens and its competitors.
Is Equasens' Research & Development too high?
Equasens' current Research & Development is €0.0 Mil. Overall, Equasens has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Equasens' Research & Development compare to VEEV and BTSG?
Equasens' Research & Development of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Equasens and its competitors. Equasens's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Based on GuruFocus' analysis, Equasens (STU:PHF) is currently considered Significantly Undervalued. The stock's GF Value™ is €55.65, compared to a current price of €34.95 — trading 37.2% below its estimated fair value. The current Research & Development is €0.0 Mil. Equasens' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Equasens (STU:PHF), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Equasens (STU:PHF) Overvalued in 2026?

Based on GuruFocus' analysis, Equasens stock appears to be undervalued. The current stock price of €34.95 is trading 37.2% below its estimated GF Value™ of €55.65. GuruFocus considers Equasens to be Significantly Undervalued.

Key valuation signals for STU:PHF:

  • Research & Development: €0.0 Mil
  • GF Value™: €55.65 vs. price of €34.95 (37.2% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the STU:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Equasens Business Description

Other Exchanges EQSp:UK0R9T:UKEQS:France
Address 5 Allee de Saint-Cloud, Technopole de Nancy Brabois, Villers-les-Nancy, FRA, 54600
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
77GF Score

Get the complete analysis for STU:PHF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.95
Price
€55.65
GF Value